CA2644297A1 - Prevention and treatment of cancer and other diseases - Google Patents

Prevention and treatment of cancer and other diseases Download PDF

Info

Publication number
CA2644297A1
CA2644297A1 CA002644297A CA2644297A CA2644297A1 CA 2644297 A1 CA2644297 A1 CA 2644297A1 CA 002644297 A CA002644297 A CA 002644297A CA 2644297 A CA2644297 A CA 2644297A CA 2644297 A1 CA2644297 A1 CA 2644297A1
Authority
CA
Canada
Prior art keywords
therapy
nucleoside analog
administering
cocktail
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002644297A
Other languages
English (en)
French (fr)
Inventor
Igor E. Bondarev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALT solutions Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/019488 external-priority patent/WO2006125166A2/en
Application filed by Individual filed Critical Individual
Publication of CA2644297A1 publication Critical patent/CA2644297A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002644297A 2006-03-14 2007-03-14 Prevention and treatment of cancer and other diseases Abandoned CA2644297A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US78255906P 2006-03-14 2006-03-14
US60/782,559 2006-03-14
US80169306P 2006-05-18 2006-05-18
US60/801,693 2006-05-18
USPCT/US2006/019488 2006-05-18
PCT/US2006/019488 WO2006125166A2 (en) 2005-05-18 2006-05-18 Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer
US86051806P 2006-11-21 2006-11-21
US60/860,518 2006-11-21
PCT/US2007/006538 WO2007106561A2 (en) 2006-03-14 2007-03-14 Prevention and treatment of cancer and other diseases

Publications (1)

Publication Number Publication Date
CA2644297A1 true CA2644297A1 (en) 2007-09-20

Family

ID=38510093

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002644297A Abandoned CA2644297A1 (en) 2006-03-14 2007-03-14 Prevention and treatment of cancer and other diseases

Country Status (5)

Country Link
US (1) US20090203636A1 (https=)
EP (1) EP2001488A4 (https=)
JP (3) JP5571947B2 (https=)
CA (1) CA2644297A1 (https=)
WO (1) WO2007106561A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106561A2 (en) * 2006-03-14 2007-09-20 Alt Solutions, Inc. Prevention and treatment of cancer and other diseases
JP2012061053A (ja) * 2010-09-14 2012-03-29 Yuuki Kitaoka 投薬装置、投薬装置の作動方法及び投薬方法
US10420761B2 (en) 2013-03-15 2019-09-24 University Of Florida Research Foundation, Inc. Allosteric inhibitors of thymidylate synthase
WO2016209688A1 (en) 2015-06-24 2016-12-29 University Of Florida Research Foundation, Incorporated Compositions for the treatment of cancer and uses thereof
WO2018013942A1 (en) * 2016-07-15 2018-01-18 Northwestern University Chromatin protective therapeutics and chromatin heterogeneity
CN110167516B (zh) * 2017-01-31 2022-08-30 金伯利-克拉克环球有限公司 包含苯甲酸酯的抗细菌组合物及利用该组合物抑制细菌生长的方法
WO2019246376A1 (en) * 2018-06-20 2019-12-26 Chernova Olga B Prevention of primary and treatment-resistant cancer by inhibitors of endogenous reverse transcriptase
EP3940075A1 (en) * 2020-07-17 2022-01-19 Istituto Nazionale Di Genetica Molecolare-INGM Inhibitors of line1 and uses thereof
EP4463151A4 (en) 2022-01-19 2025-10-01 Univ Northwestern Agents Targeting Telomerase Reverse Transcriptase (TERT) to Treat Cancer and Sensitize Cancer Cells to Genotoxic Therapy
WO2025260081A1 (en) * 2024-06-14 2025-12-18 Northwestern University Targeted degraders of telomerase reverse transcriptase (tert) and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
GB1523865A (en) * 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
US4347360A (en) * 1980-09-16 1982-08-31 Ens Bio Logicals Inc. Ring open nucleoside analogues
JPS61254526A (ja) * 1985-05-07 1986-11-12 Teijin Ltd 経口投与用抗腫瘍剤
DE3665260D1 (en) * 1985-05-07 1989-10-05 Teijin Ltd Antitumor agent
JPH06509578A (ja) * 1991-07-26 1994-10-27 ユニバーシティ・オブ・ロチェスター 悪性細胞利用による癌治療法
AU2002360697B2 (en) * 2001-12-20 2009-04-23 Beth Israel Deaconess Medical Center Treatment of EBV and KHSV infection and associated abnormal cellular proliferation
US20050113324A1 (en) * 2003-01-15 2005-05-26 Bondarev Igor E. Modulation of line-1 reverse transcriptase
US20050026902A1 (en) * 2003-01-31 2005-02-03 Timothy Maziasz Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
CA2602562C (en) * 2005-03-25 2015-07-07 Alt Solutions, Inc. Modulation of telomere length in telomerase positive cells and cancer therapy
CN101588805A (zh) * 2005-05-18 2009-11-25 Alt解决方案公司 为预防和治疗癌症对癌细胞中端粒长度的药理学调节
WO2007106561A2 (en) * 2006-03-14 2007-09-20 Alt Solutions, Inc. Prevention and treatment of cancer and other diseases

Also Published As

Publication number Publication date
EP2001488A4 (en) 2009-11-25
JP2014144962A (ja) 2014-08-14
WO2007106561A2 (en) 2007-09-20
JP2016175917A (ja) 2016-10-06
JP5571947B2 (ja) 2014-08-13
US20090203636A1 (en) 2009-08-13
JP2009530295A (ja) 2009-08-27
EP2001488A2 (en) 2008-12-17
WO2007106561A3 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
CA2644297A1 (en) Prevention and treatment of cancer and other diseases
ES2630002T3 (es) Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa
RU2587013C2 (ru) Комбинированная химиотерапия
JP6364546B2 (ja) 抗腫瘍剤の副作用軽減剤
US20070232592A1 (en) Therapeutic Compositions Containing at Least one Pyrrolobenzodiazepine Derivative and Fludarabine
US20110218170A1 (en) Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
Blanke et al. Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer.
JP2009530295A5 (https=)
JP2014144962A5 (https=)
US6503889B2 (en) Composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
US20130196938A1 (en) Combination comprising cndac (2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosine) and a cytotoxic agent
JP4610481B2 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
JP2015504079A (ja) 還元型フォレート、たとえばメチレン−テトラヒドロフォレートの抗腫瘍活性
US20070036717A1 (en) Chemoradiotherapy with TS-1/camptothecins
TW200306185A (en) Combinations comprising EPOTHILONES and anti-metabolites
CN101355969B (zh) 包含cyc-682和细胞毒性药物的抗增殖性组合
JP6845332B2 (ja) がん治療用医薬組成物及びその使用
EP2268287B1 (en) Dosage regimens of an antitumor agent comprising deoxycytidine derivative
JP2013508293A (ja) ５−ｆｕ又はそのプロドラッグと、ｄｐｄ阻害剤との組合せに付随した神経毒性の処置
US20240173323A1 (en) Combination therapy for cancer treatment
RU2471486C2 (ru) Противоопухолевое средство для непрерывного внутривенного введения, содержащее цитидиновое производное
KR20060036058A (ko) 결장직장암의 치료를 위한 혈관 손상 활성을 갖는 5ｆｕ,ｃｐｔ-11 또는 5-ｆｕ 및 ｃｐｔ-11과 함께 ｚｄ6126을포함하는 조성물
KR20120015318A (ko) 테가푸르?기메라실?오테라실칼륨 배합제 및 옥살리플라틴을 함유하는 항종양제
Montalar et al. Vinorelbine (VNR), ifosfamide (IFO) and cisplatin (CDDP) as assitencial treatment in patients (PTS) with inoperable non small cell lung cancer (NSCLC)
ZA200206864B (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20170314